当前位置:产品中心 > 抗体 > Biosimilar抗体 > 细胞因子 > Anti-IL-12/23(p40) hIgG1 Reference Antibody (Ustebio)
Anti-IL-12/23(p40) hIgG1 Reference Antibody (Ustebio)
基本信息

产品编号:GM-87870MAB

产品名称:Anti-IL-12/23(p40) hIgG1 Reference Antibody (Ustebio)

目录价:询价

产品配图.jpg


Cat. No. & Size

GM-87870MAB-1mg / 1 mg

GM-87870MAB-5mg / 5 mg

GM-87870MAB-25mg / 25 mg

GM-87870MAB-50mg / 50 mg

GM-87870MAB-100mg / 100 mg



产品简介

Expression System

CHO

Aggregation

< 5% as determined by SEC-HPLC

Purity

> 95% as determined by SDS-PAGE

Endotoxin

< 1 EU/mg, determined by LAL gel clotting assay

Sterility

0.2 μm Filtered

Target

IL-12& IL-23

Clone

Ustekinumab

Source/Isotype

Monoclonal Human IgG1, Kappa

Application

Bioactivity-ELISA; Block assay

Description

Ustekinumab (brand name: Stelara) is a fully human IgG1κ monoclonal antibody developed by Janssen Biotech, a subsidiary of Johnson & Johnson. It is used to treat various immune-mediated diseases, such as psoriasis, psoriatic arthritis, and Crohn's disease. It exerts its immunomodulatory effects by specifically inhibiting the activity of the pro-inflammatory cytokines IL-12 and IL-23.

Formulation

phosphate-buffered solution, pH 7.2-7.4.


数据展示


image.png

image.png

image.png

image.png

image.png

image.png

image.png

当前位置:产品中心 > 抗体 > Biosimilar抗体 > Anti-IL-12/23(p40) hIgG1 Reference Antibody (Ustebio)

Anti-IL-12/23(p40) hIgG1 Reference Antibody (Ustebio)
基本信息

产品编号:GM-87870MAB

产品名称:Anti-IL-12/23(p40) hIgG1 Reference Antibody (Ustebio)

目录价:询价

产品配图.jpg


Cat. No. & Size

GM-87870MAB-1mg / 1 mg

GM-87870MAB-5mg / 5 mg

GM-87870MAB-25mg / 25 mg

GM-87870MAB-50mg / 50 mg

GM-87870MAB-100mg / 100 mg



产品简介

Expression System

CHO

Aggregation

< 5% as determined by SEC-HPLC

Purity

> 95% as determined by SDS-PAGE

Endotoxin

< 1 EU/mg, determined by LAL gel clotting assay

Sterility

0.2 μm Filtered

Target

IL-12& IL-23

Clone

Ustekinumab

Source/Isotype

Monoclonal Human IgG1, Kappa

Application

Bioactivity-ELISA; Block assay

Description

Ustekinumab (brand name: Stelara) is a fully human IgG1κ monoclonal antibody developed by Janssen Biotech, a subsidiary of Johnson & Johnson. It is used to treat various immune-mediated diseases, such as psoriasis, psoriatic arthritis, and Crohn's disease. It exerts its immunomodulatory effects by specifically inhibiting the activity of the pro-inflammatory cytokines IL-12 and IL-23.

Formulation

phosphate-buffered solution, pH 7.2-7.4.


数据展示


image.png

image.png

image.png

image.png

image.png

image.png

image.png

Tel: 400-627-9288
留言咨询
重置
提交
客服
微信
电话
留言
留言咨询
重置
提交